Bristol-Myers Squibb Company

Análisis de la acción Bristol-Myers Squibb Company (BMY)

$61.120

-0.556 (-0.91%)Al cierre

Loading chart…
Máximo
61.809
Apertura
61.500
Precio medio ponderado por volumen
61.20
Volumen
9.02M
Capitalización
84.14B
Mínimo
60.685
Importe
551.85M
EV/EBITDA, TTM
8.06

Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development, and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Orencia (abatacept), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Breyanzi (lisocabtagene maraleucel), Opdualag (nivolumab and relatlimab-rmbw), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), Sotyktu (deucravacitinib), Krazati (adagrasib), and Cobenfy (xanomeline and trospium chloride). Its other growth products include Augtyro, Onureg, Inrebic, Nulojix, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension).

www.bms.com

Análisis de IA of Bristol-Myers Squibb Company (BMY)

Comprar

Bristol-Myers Squibb Co is a good buy right now due to its current price of $59.75, which is well below the analyst price target of $76 from Jefferies, indicating a potential upside of 27%. Additionally, the forward P/E ratio of 9.36 suggests that the stock is undervalued compared to its earnings potential. The main risk comes from the company's net margin of 14.6%, which, while improved, indicates ongoing challenges in profitability.

Recomendaciones de analistas (22)

-8.61% Potencial de caída
Mantener
9 Comprar
11 Mantener
2 Vender
Actual: 61.12
Mínimo
37.00
Promedio
55.86
Máximo
68.00

Jefferies

2026-10-12

Precio objetivo

$76

Comprar

William Blair

2026-10-12

Precio objetivo

—

Market Perform

BofA

2026-10-09

Precio objetivo

$66

Comprar

Cantor Fitzgerald

2026-10-08

Precio objetivo

$53

Neutral

Morgan Stanley

2026-10-07

Precio objetivo

$41

Infraponderar

Métricas de valoración

El PER previsto actual de Bristol-Myers Squibb Company (BMY) es 9.36, frente a su media de 5 años de 11.39.

PER previsto

Valor razonable
Media 5A P/E
11.39
P/E actual
9.36
Sobrevalorada
24.95
Infravalorada
-2.18

EV/EBITDA previsto

Valor razonable
Media 5A EV/EBITDA
10.20
EV/EBITDA actual
8.06
Sobrevalorada
14.39
Infravalorada
6.02

Precio/ventas previsto

Valor razonable
Media 5A P/S
2.67
P/S actual
2.59
Sobrevalorada
3.19
Infravalorada
2.15

Escenarios de precio de Alphio AI para BMY

Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.

A

Alcista

Alcista · 25%BMY

$44.66

Precio del escenario

B

Base

Base · 50%BMY

$40.66

Precio del escenario

B

Bajista

Bajista · 25%BMY

$35.77

Precio del escenario

Ballenas con BMY en cartera

T

Turtle Creek Management, LLC

+ Con en carteraBMY

+21.64%

Rentabilidad a 3 meses

C

Cbus Industry Superannuation Fund

+ Con en carteraBMY

+12.14%

Rentabilidad a 3 meses

B

Blackhill Capital, Inc

+ Con en carteraBMY

+10.21%

Rentabilidad a 3 meses

S

Sofinnova Investments, Inc.

+ Con en carteraBMY

+10.08%

Rentabilidad a 3 meses

A

Acadian Asset Management LLC

+ Con en carteraBMY

+9.85%

Rentabilidad a 3 meses

H

Harvest Portfolios Group Inc.

+ Con en carteraBMY

+8.87%

Rentabilidad a 3 meses

Cronología de eventos

2026-10-15 (ET)

14:30:00

Applied Intuition Valued at $30B, Plans to Raise Over $1B

2026-10-12 (ET)

14:00:00

RBC Analyst Calls Bristol Myers Drug Results Positive

09:00:00

S&P 500 Futures Mixed as Oil Prices Rise

07:00:00

Bristol Myers Squibb Announces Positive ACTION-1 Trial Results

07:00:00

Bristol Myers Squibb Announces Phase 3 Trial Results for Admilparant

Noticias

Preguntas frecuentes sobre BMY, respondidas por Alphio AI

Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development, and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Orencia (abatacept), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Breyanzi (lisocabtagene maraleucel), Opdualag (nivolumab and relatlimab-rmbw), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), Sotyktu (deucravacitinib), Krazati (adagrasib), and Cobenfy (xanomeline and trospium chloride). Its other growth products include Augtyro, Onureg, Inrebic, Nulojix, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Bristol-Myers Squibb Co is a good buy right now due to its current price of $59.75, which is well below the analyst price target of $76 from Jefferies, indicating a potential upside of 27%. Additionally, the forward P/E ratio of 9.36 suggests that the stock is undervalued compared to its earnings potential. The main risk comes from the company's net margin of 14.6%, which, while improved, indicates ongoing challenges in profitability.

22 analysts cover BMY: 9 rate it Buy, 11 Hold and 2 Sell. The average price target is 55.86.

Comunidad

Más ↗
molten_vortex26/9/2026

Innovation Is Driving a New Bull Market in Biotech. 16 Ways to Play It, From Our Roundtable Experts. Biotechnology stocks are soaring this year as medical advances and merger activity rekindle investor interest. More gains lie ahead, our healthcare panel says. A tidal wave of innovation in biotechnology is improving patient outcomes, transforming the industry's prospects, and lifting long-suffering biotech shares. Spurred by therapeutic breakthroughs and new-product launches, investors have bid up the iShares Biotechnology, or IBB, by 24% this year, while the State Street SPDR S&P Biotech ETF, or XBI, has risen 28%, more than twice the gain of the S&P 500. Large pharmaceutical companies are also paying attention. They have been striking licensing deals with smaller biotechs and scooping up whole companies in a bid to rebuild their pipelines and replace blockbuster drugs facing patent expirations. $MRNA $MRK $RVMD $BMY $SMMT

Mostrar más
RektEddy15/9/2026

$PGR $SYK $BMY Many people enter the crypto space chasing quick profits, but real, consistent success is built on knowledge, discipline, and the right guidance. That’s where having a reliable mentor makes all the difference. Craig has played a key role in helping me understand the markets with more clarity and confidence. His approach to trading goes beyond signals, it’s about building structure, managing risk, and staying focused on long-term growth. With his guidance and his YouTube videos, I’ve been able to make smarter decisions, avoid emotional trading, and stay consistent even in volatile conditions. The shift in mindset alone has been a game changer.

Mostrar más
Regístrate o inicia sesión para participar

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empezar a operar